Literature DB >> 930746

CNS compensation to dopamine neuron loss in Parkinson's disease.

K G Lloyd.   

Abstract

Postmortem studies in brains from parkinsonian patients consistently reveal a minimum loss of 75% of the nigrostriatal dopamine neurons. This indicates that over a prolonged period, before Parkinson's disease is clinically evident, there is a physiological compensation for the slow loss of dopamine neurons (i.e. compensated stage of Parkinson's disease). Only when the dopamine neuron loss is sufficiently severe (greater than 75% of nigrostriatal dopamine neurons) does the disease become clinically evident (decompensated state). Postmortem examination of Parkinson's disease brains and study of animal models indicate that the following mechanisms may contribute to this CNS compensation: 1) A decrease in striatal cholinergic activity, in an attempt to maintain a critical DA:ACh balance; and 2) A decrease in activity of GABA neurons in the striatum and substantia nigra, resulting in an increased firing rate of nigral dopamine cells. These mechanisms allow the brain to readjust to the initial dopamine cell loss in Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 930746     DOI: 10.1007/978-1-4684-2511-6_16

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  A new mouse model to study compensatory mechanisms that support normal motor function in Parkinson's disease.

Authors:  Xiang Bai; Stacy A Hussong
Journal:  J Biochem Pharmacol Res       Date:  2014-06

2.  MP4- and MOG:35-55-induced EAE in C57BL/6 mice differentially targets brain, spinal cord and cerebellum.

Authors:  Stefanie Kuerten; Dilyana A Kostova-Bales; Lukas P Frenzel; Justine T Tigno; Magdalena Tary-Lehmann; Doychin N Angelov; Paul V Lehmann
Journal:  J Neuroimmunol       Date:  2007-07-25       Impact factor: 3.478

3.  Increased abundance of alternatively spliced forms of D2 dopamine receptor mRNA after denervation.

Authors:  K A Neve; R L Neve; S Fidel; A Janowsky; G A Higgins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-04-01       Impact factor: 11.205

4.  Acute neuronal apoptosis in a rat model of multiple sclerosis.

Authors:  R Meyer; R Weissert; R Diem; M K Storch; K L de Graaf; B Kramer; M Bahr
Journal:  J Neurosci       Date:  2001-08-15       Impact factor: 6.167

Review 5.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 6.  NADPH oxidases in Parkinson's disease: a systematic review.

Authors:  Karim Belarbi; Elodie Cuvelier; Alain Destée; Bernard Gressier; Marie-Christine Chartier-Harlin
Journal:  Mol Neurodegener       Date:  2017-11-13       Impact factor: 14.195

7.  Dissociable effects of dopamine on neuronal firing rate and synchrony in the dorsal striatum.

Authors:  John M Burkhardt; Xin Jin; Rui M Costa
Journal:  Front Integr Neurosci       Date:  2009-10-30

8.  Inhibition of Vascular Endothelial Growth Factor Receptor 2 Exacerbates Loss of Lower Motor Neurons and Axons during Experimental Autoimmune Encephalomyelitis.

Authors:  Milos Stanojlovic; Xiaosha Pang; Yifeng Lin; Sarrabeth Stone; Marija Cvetanovic; Wensheng Lin
Journal:  PLoS One       Date:  2016-07-28       Impact factor: 3.240

9.  Neuropeptide Treatment with Cerebrolysin Enhances the Survival of Grafted Neural Stem Cell in an α-Synuclein Transgenic Model of Parkinson's Disease.

Authors:  Edward Rockenstein; Paula Desplats; Kiren Ubhi; Michael Mante; Jazmin Florio; Anthony Adame; Stefan Winter; Hemma Brandstaetter; Dieter Meier; Herbert Moessler; Eliezer Masliah
Journal:  J Exp Neurosci       Date:  2016-07-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.